About the Company:
Company (Headquartered in Ankleshwar, Gujarat) and is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry.
Shree Ganesh Remedies Ltd is as ISO 9001:2015, ISO 14001:2015 BS and OHSAS 18001:2007 certified Company.
Company manufactures products relating to antipsychotic,antiseptic, deprotonation reactions, hyperlipidemia, alzheimers and anti-viral.
The Products are manufactured for export market and also for domestic and foreign markets. They had entered the International market in the year 2006 and are on regular basis exporting their products to various countries.
The manufacturing process is supported by Total Quality Management techniques and is supervised through various quality control equipment’s and qualified personnel.
Company’s manufacturing facility is divided into three manufacturing plants namely Plant I, II and III spread across 9715 square meters having different product manufacturing capabilities and process.
- Mr.Chandubhai Kothia (Designation:Promoter, Chairman & Managing Director)
- Mr.Hasmukh Kothia (Designation: Executive Director)
- Mr.Ashokkumar Kothia (Designation:Executive Director)
Promoters Stake Pre & Post Issue:
|Shareholder Name||Pre Issue Stake (%)||Post Issue Stake|
|Promoter Group Entities||21.37%||15.71%|
Strengths of the Company:
- Experienced Promoters.
- Quality Assurance.
- Efficient management team.
- Well-equipped manufacturing facility.
- Long term relationships with customers.
Comparison of Peer Group Companies:
|Company Name||EPS||PE Ratio||RoNW(%)||NAV|
|Ishita Drugs & Industries Ltd||0.61||31.07||3.14||19.44|
|Bhagiradha Chemicals Industries Ltd||4.01||48.63||4.21||95.35|
|Aarti Industries Ltd||37.35||22.92||23.41||159.53|
|Shree Ganesh Remedies Ltd||3.96||9.09||15.81||25.07|
Objectives of the Issue:
- Setting up a new Choloro Compound derivatives manufacturing plant at Ankleshwar GIDC Gujarat.
- General Corporate Purposes.
- Listing Benefits.
|Particulars||Amount (Rs. in Lakhs)|
|Setting up a new Choloro Compound derivatives
manufacturing plant at Ankleshwar GIDC Gujarat
|General Corporate Expenses||112.36|
Financials of the Company:
|(in Crores)||FY 13||FY 14||FY 15||FY 16||FY 17|
|Issue Opens on||28th September 2017|
|Issue Closes on||5th October 2017|
|Issue Size||Rs.9.68 cr|
|Market Cap||Rs.32.29 cr|
|Listing at||BSE SME|
|Equity Shares Offered||23,76,000|
|Equity Shares Prior||65,95,356|
|Equity Shares after the issue||89,71,356|
|Finalization of Basis of Alottment||on or Before 10th October 2017|
|Allotment/Initiation of Refunds||on or Before 11th October 2017|
|Credit of Equity Shares:||on or Before 12th October 2017|
|Listing Date:||on or Before 13th October 2017|
IPO Valuation Parameters:
|Earnings Per Share (EPS)||Price To Earnings ratio (PE)||Return on Net Worth (RoNW)||Net Asset Value (NAV)|
Markets Guruji Opinion:
|IPO View||Apply For:||Expected listing Gain:|